286PFirst china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). (25th November 2018)

Record Type:: Journal Article
Title:: 286PFirst china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). (25th November 2018)
Main Title:: 286PFirst china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics)
Authors:: Shi, Y
Zhang, Q
Han, X
Song, Y
Qin, Y
Hong, X
Ke, X
Feng, J
Wang, D
Li, W
Su, H
Zhang, Y
Zhang, H
Yang, J
Liu, L
Zhang, X
Liu, E
Jiang, W
Liu, S
Luk, A
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 9
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 9
Issue Display:: Volume 29, Issue 9 (2018)
Year:: 2018
Volume:: 29
Issue:: 9
Issue Sort Value:: 2018-0029-0009-0000
Page Start:
Page End:
Publication Date:: 2018-11-25
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy437.005 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12251.xml